167 related articles for article (PubMed ID: 38673831)
1. Preclinical Evaluation of HER2-Targeting DARPin G3: Impact of Albumin-Binding Domain (ABD) Fusion.
Deyev SM; Oroujeni M; Garousi J; Gräslund T; Li R; Rosly AHB; Orlova A; Konovalova E; Schulga A; Vorobyeva A; Tolmachev V
Int J Mol Sci; 2024 Apr; 25(8):. PubMed ID: 38673831
[TBL] [Abstract][Full Text] [Related]
2. Site-specific radiometal labeling and improved biodistribution using ABY-027, a novel HER2-targeting affibody molecule-albumin-binding domain fusion protein.
Orlova A; Jonsson A; Rosik D; Lundqvist H; Lindborg M; Abrahmsen L; Ekblad C; Frejd FY; Tolmachev V
J Nucl Med; 2013 Jun; 54(6):961-8. PubMed ID: 23528382
[TBL] [Abstract][Full Text] [Related]
3. Development of the designed ankyrin repeat protein (DARPin) G3 for HER2 molecular imaging.
Goldstein R; Sosabowski J; Livanos M; Leyton J; Vigor K; Bhavsar G; Nagy-Davidescu G; Rashid M; Miranda E; Yeung J; Tolner B; Plückthun A; Mather S; Meyer T; Chester K
Eur J Nucl Med Mol Imaging; 2015 Feb; 42(2):288-301. PubMed ID: 25391547
[TBL] [Abstract][Full Text] [Related]
4. The influence of Bz-DOTA and CHX-A''-DTPA on the biodistribution of ABD-fused anti-HER2 Affibody molecules: implications for (114m)In-mediated targeting therapy.
Tolmachev V; Wållberg H; Andersson K; Wennborg A; Lundqvist H; Orlova A
Eur J Nucl Med Mol Imaging; 2009 Sep; 36(9):1460-8. PubMed ID: 19430786
[TBL] [Abstract][Full Text] [Related]
5. Radionuclide therapy of HER2-positive microxenografts using a 177Lu-labeled HER2-specific Affibody molecule.
Tolmachev V; Orlova A; Pehrson R; Galli J; Baastrup B; Andersson K; Sandström M; Rosik D; Carlsson J; Lundqvist H; Wennborg A; Nilsson FY
Cancer Res; 2007 Mar; 67(6):2773-82. PubMed ID: 17363599
[TBL] [Abstract][Full Text] [Related]
6. Homogeneous tumor targeting with a single dose of HER2-targeted albumin-binding domain-fused nanobody-drug conjugates results in long-lasting tumor remission in mice.
Xenaki KT; Dorrestijn B; Muns JA; Adamzek K; Doulkeridou S; Houthoff H; Oliveira S; van Bergen En Henegouwen PM
Theranostics; 2021; 11(11):5525-5538. PubMed ID: 33859761
[No Abstract] [Full Text] [Related]
7. Comparison of tumor‑targeting properties of directly and indirectly radioiodinated designed ankyrin repeat protein (DARPin) G3 variants for molecular imaging of HER2.
Vorobyeva A; Sсhulga A; Konovalova E; Güler R; Mitran B; Garousi J; Rinne S; Löfblom J; Orlova A; Deyev S; Tolmachev V
Int J Oncol; 2019 Apr; 54(4):1209-1220. PubMed ID: 30968147
[TBL] [Abstract][Full Text] [Related]
8. Radionuclide therapy using ABD-fused ADAPT scaffold protein: Proof of Principle.
Garousi J; von Witting E; Borin J; Vorobyeva A; Altai M; Vorontsova O; Konijnenberg MW; Oroujeni M; Orlova A; Tolmachev V; Hober S
Biomaterials; 2021 Jan; 266():120381. PubMed ID: 33120197
[TBL] [Abstract][Full Text] [Related]
9. Comparative Preclinical Evaluation of HYNIC-Modified Designed Ankyrin Repeat Proteins
Larkina M; Varvashenya R; Yuldasheva F; Plotnikov E; Bezverkhniaia E; Tretyakova M; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Belousov M; Orlova A; Tolmachev V; Deyev S
Mol Pharm; 2024 Apr; 21(4):1919-1932. PubMed ID: 38557163
[TBL] [Abstract][Full Text] [Related]
10. Indirect Radioiodination of DARPin G3 Using N-succinimidyl-
Vorobyeva A; Schulga A; Rinne SS; Günther T; Orlova A; Deyev S; Tolmachev V
Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234471
[TBL] [Abstract][Full Text] [Related]
11. Optimal composition and position of histidine-containing tags improves biodistribution of
Vorobyeva A; Schulga A; Konovalova E; Güler R; Löfblom J; Sandström M; Garousi J; Chernov V; Bragina O; Orlova A; Tolmachev V; Deyev SM
Sci Rep; 2019 Jun; 9(1):9405. PubMed ID: 31253840
[TBL] [Abstract][Full Text] [Related]
12. Comparative Evaluation of Two DARPin Variants: Effect of Affinity, Size, and Label on Tumor Targeting Properties.
Deyev S; Vorobyeva A; Schulga A; Proshkina G; Güler R; Löfblom J; Mitran B; Garousi J; Altai M; Buijs J; Chernov V; Orlova A; Tolmachev V
Mol Pharm; 2019 Mar; 16(3):995-1008. PubMed ID: 30608701
[TBL] [Abstract][Full Text] [Related]
13. Comparative Preclinical Evaluation of HER2-Targeting ABD-Fused Affibody
Liu Y; Vorobyeva A; Xu T; Orlova A; Loftenius A; Bengtsson T; Jonasson P; Tolmachev V; Frejd FY
Pharmaceutics; 2021 Jun; 13(6):. PubMed ID: 34200197
[TBL] [Abstract][Full Text] [Related]
14. Sortase-Mediated Site-Specific Conjugation and
Fay R; Törő I; Schinke AL; Simic B; Schaefer JV; Dreier B; Plückthun A; Holland JP
Mol Pharm; 2022 Oct; 19(10):3576-3585. PubMed ID: 35434995
[TBL] [Abstract][Full Text] [Related]
15. Comparative Evaluation of Radioiodine and Technetium-Labeled DARPin 9_29 for Radionuclide Molecular Imaging of HER2 Expression in Malignant Tumors.
Vorobyeva A; Bragina O; Altai M; Mitran B; Orlova A; Shulga A; Proshkina G; Chernov V; Tolmachev V; Deyev S
Contrast Media Mol Imaging; 2018; 2018():6930425. PubMed ID: 29977173
[TBL] [Abstract][Full Text] [Related]
16. Comparative Preclinical Evaluation of Peptide-Based Chelators for the Labeling of DARPin G3 with
Larkina M; Plotnikov E; Bezverkhniaia E; Shabanova Y; Tretyakova M; Yuldasheva F; Zelchan R; Schulga A; Konovalova E; Vorobyeva A; Garousi J; Gräslund T; Belousov M; Tolmachev V; Deyev S
Int J Mol Sci; 2022 Nov; 23(21):. PubMed ID: 36362226
[TBL] [Abstract][Full Text] [Related]
17. Direct In Vivo Comparison of
Tolmachev V; Bodenko V; Oroujeni M; Deyev S; Konovalova E; Schulga A; Lindbo S; Hober S; Bragina O; Orlova A; Vorobyeva A
Int J Mol Sci; 2022 Dec; 23(23):. PubMed ID: 36499504
[TBL] [Abstract][Full Text] [Related]
18. Affibody-conjugated 5-fluorouracil prodrug system preferentially targets and inhibits HER2-expressing cancer cells.
Lan KH; Tsai CL; Chen YY; Lee TL; Pai CW; Chao Y; Lan KL
Biochem Biophys Res Commun; 2021 Dec; 582():137-143. PubMed ID: 34710829
[TBL] [Abstract][Full Text] [Related]
19. Multifunctional superparamagnetic nanoparticles conjugated with fluorescein-labeled designed ankyrin repeat protein as an efficient HER2-targeted probe in breast cancer.
Li DL; Tan JE; Tian Y; Huang S; Sun PH; Wang M; Han YJ; Li HS; Wu HB; Zhang XM; Xu YK; Wang QS
Biomaterials; 2017 Dec; 147():86-98. PubMed ID: 28938164
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
